Pyxis Oncology, Inc. PYXS
1.58 USD 0.00 (+0.00%)
Regular-session close
1.66 +0.08 +5.06%
Pre-market · Nov 16, 7:22 AM ET
1.52 Day range 1.60
1.03 52-week range 5.55
- YTD
- +37.39%
- 1 year
- -64.73%
News
benzinga.com RBC Capital Maintains Outperform on Pyxis Oncology, Raises Price Target to $7 RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $7.
benzinga.com Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7 Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $7.
benzinga.com Pyxis Oncology Q3 EPS $(0.24) Beats $(0.29) Estimate Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 31.43 percent increase over losses of…
benzinga.com Pyxis Oncology To Present Late-Breaking Oral Data On MICVO Monotherapy In Previously Treated Recurrent/Metastatic Head And Neck Cancer At EORTC-NCI-AACR Symposium Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart…
